• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多西环素在 COVID-19 治疗中的再利用的潜在效果和不良影响。

Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment.

机构信息

Cholera and Biofilm Research Laboratory, Pathogen Biology Group, Rajiv Gandhi Centre for Biotechnology, Thiruvananthapuram, India.

出版信息

Expert Rev Anti Infect Ther. 2021 Aug;19(8):1001-1008. doi: 10.1080/14787210.2021.1865803. Epub 2020 Dec 24.

DOI:10.1080/14787210.2021.1865803
PMID:33322952
Abstract

: COVID-19 infection with no known-specific drugs or vaccines has impacted mankind and has become beyond precedence. Currently, re-purposing of existing drugs is the only therapeutic option for managing COVID-19 symptoms and associated co-infections to reduce mortality. Antimicrobials as varied as antiparasitic, antiviral, and antibiotics are under various stages of evaluation.: Recently, doxycycline, a broad-spectrum antibiotic that has also reported antiviral and anti-inflammatory properties was widely investigated in clinical trials, either alone or in combination with other drugs, and repurposed for COVID-19 treatment. In the review, the potential therapeutic applications of doxycycline in COVID-19 treatment and its potential adverse implications with respect to antimicrobial resistance bestowed by repurposing the antibiotic have been expounded.: 'Fighting disease with already existing antibiotics' and 'antimicrobial resistance progression' are like two arms of a balance that has to be carefully equilibrated. Any imbalance by the inappropriate or indiscriminate use of the repurposed drugs would cause a disastrous increase in antimicrobial resistance (AMR). Hence, cautious parallel assessment of potential long-term consequences of AMR is of great importance to mankind as its impacts would prevail even after the current pandemic.

摘要

: 没有已知特效药物或疫苗的 COVID-19 感染对人类造成了前所未有的影响。目前,重新利用现有药物是管理 COVID-19 症状和相关合并感染以降低死亡率的唯一治疗选择。各种抗生素、抗病毒药物和抗寄生虫药物都处于不同的评估阶段。: 最近,一种广谱抗生素多西环素因其具有抗病毒和抗炎特性而受到广泛研究,无论是单独使用还是与其他药物联合使用,都被重新用于 COVID-19 的治疗。在综述中,阐述了多西环素在 COVID-19 治疗中的潜在治疗应用及其在重新利用抗生素方面对抗微生物药物耐药性的潜在不良影响。: “用现有的抗生素治疗疾病”和“抗微生物药物耐药性的进展”就像天平的两个臂,必须小心地平衡。任何不合理或不分青红皂白地使用重新利用的药物都会导致抗微生物药物耐药性(AMR)灾难性地增加。因此,谨慎评估 AMR 的潜在长期后果对人类来说非常重要,因为即使在当前大流行之后,其影响仍将持续存在。

相似文献

1
Potential effectiveness and adverse implications of repurposing doxycycline in COVID-19 treatment.多西环素在 COVID-19 治疗中的再利用的潜在效果和不良影响。
Expert Rev Anti Infect Ther. 2021 Aug;19(8):1001-1008. doi: 10.1080/14787210.2021.1865803. Epub 2020 Dec 24.
2
Repurposing of antibiotics for clinical management of COVID-19: a narrative review.抗生素在 COVID-19 临床治疗中的再利用:叙述性综述。
Ann Clin Microbiol Antimicrob. 2021 May 21;20(1):37. doi: 10.1186/s12941-021-00444-9.
3
Combating COVID-19: The role of drug repurposing and medicinal plants.抗击 COVID-19:药物再利用和药用植物的作用。
J Infect Public Health. 2021 Apr;14(4):495-503. doi: 10.1016/j.jiph.2020.10.012. Epub 2020 Oct 27.
4
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.具有潜在重新用于靶向 COVID-19 能力的现有高积累溶酶体靶向药物。
Biomed Pharmacother. 2020 Oct;130:110582. doi: 10.1016/j.biopha.2020.110582. Epub 2020 Jul 30.
5
Repurposing therapeutic agents against SARS-CoV-2 infection: most promising and neoteric progress.针对 SARS-CoV-2 感染的治疗药物再利用:最有前途和新颖的进展。
Expert Rev Anti Infect Ther. 2021 Aug;19(8):1009-1027. doi: 10.1080/14787210.2021.1864327. Epub 2020 Dec 23.
6
Doxycycline as an Alternative to Azithromycin in Elderly Patients.多西环素作为老年患者阿奇霉素的替代药物
Int J Antimicrob Agents. 2021 Jan;57(1):106168. doi: 10.1016/j.ijantimicag.2020.106168.
7
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics.一种评估药物用于 COVID-19 治疗药物再利用潜力的药物代谢动力学方法。
Expert Rev Clin Pharmacol. 2022 Aug;15(8):945-958. doi: 10.1080/17512433.2022.2113388. Epub 2022 Sep 4.
8
Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19.利用临床药理学在药物再利用领域:看看 COVID-19。
Expert Rev Clin Pharmacol. 2022 Oct;15(10):1225-1231. doi: 10.1080/17512433.2022.2132226. Epub 2022 Oct 8.
9
Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications.重新利用四环素类药物治疗急性呼吸窘迫综合征(ARDS)和严重 COVID-19:对近期出版物的批判性讨论。
Expert Opin Investig Drugs. 2022 May;31(5):475-482. doi: 10.1080/13543784.2022.2054325. Epub 2022 Mar 23.
10
Safety perspectives on presently considered drugs for the treatment of COVID-19.目前用于治疗 COVID-19 的药物的安全性观察。
Br J Pharmacol. 2020 Oct;177(19):4353-4374. doi: 10.1111/bph.15204. Epub 2020 Aug 13.

引用本文的文献

1
Impact of easing COVID-19 restrictions on antibiotic usage in Eastern China using wastewater-based epidemiology.利用基于污水的流行病学研究放宽 COVID-19 限制措施对中国东部地区抗生素使用的影响。
Nat Commun. 2024 Nov 23;15(1):10161. doi: 10.1038/s41467-024-54498-2.
2
Drug modifications: graphene oxide-chitosan loading enhanced anti-amoebic effects of pentamidine and doxycycline.药物修饰:氧化石墨烯-壳聚糖负载增强了戊脒和强力霉素的抗阿米巴效果。
Parasitol Res. 2024 Nov 20;123(11):387. doi: 10.1007/s00436-024-08389-6.
3
Doxycycline-Mediated Inhibition of Snake Venom Phospholipase and Metalloproteinase.
多西环素介导的蛇毒磷脂酶和金属蛋白酶抑制作用。
Mil Med. 2024 Nov 5;189(11-12):e2430-e2438. doi: 10.1093/milmed/usae184.
4
Doxycycline's Potential Role in Reducing Thrombosis and Mortality in Critically Ill Patients With COVID-19: A Multicenter Cohort Study.多西环素在降低 COVID-19 危重症患者血栓形成和死亡率中的潜在作用:一项多中心队列研究。
Clin Appl Thromb Hemost. 2023 Jan-Dec;29:10760296231177017. doi: 10.1177/10760296231177017.
5
Interaction of Epigallocatechin Gallate and Quercetin with Spike Glycoprotein (S-Glycoprotein) of SARS-CoV-2: In Silico Study.表没食子儿茶素没食子酸酯和槲皮素与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突糖蛋白(S糖蛋白)的相互作用:计算机模拟研究
Biomedicines. 2022 Nov 29;10(12):3074. doi: 10.3390/biomedicines10123074.
6
Current Treatments for COVID-19: Application of Supercritical Fluids in the Manufacturing of Oral and Pulmonary Formulations.新型冠状病毒肺炎的当前治疗方法:超临界流体在口服和肺部制剂生产中的应用
Pharmaceutics. 2022 Nov 4;14(11):2380. doi: 10.3390/pharmaceutics14112380.
7
Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.在 COVID-19 治疗中作为 RdRp 抑制剂处于临床试验阶段的药物的最新研究进展和分子对接研究。
Curr Pharm Des. 2022;28(46):3677-3705. doi: 10.2174/1381612829666221107123841.
8
Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.已批准的抗菌、抗真菌、抗原虫和抗蠕虫药物的抗病毒活性:抗病毒药物发现中药物重新利用的机会。
J Exp Pharmacol. 2022 Mar 8;14:97-115. doi: 10.2147/JEP.S346006. eCollection 2022.
9
VDA-RWLRLS: An anti-SARS-CoV-2 drug prioritizing framework combining an unbalanced bi-random walk and Laplacian regularized least squares.VDA-RWLRLS:一种结合非平衡双向随机游走和拉普拉斯正则化最小二乘法的抗SARS-CoV-2药物优先级框架。
Comput Biol Med. 2022 Jan;140:105119. doi: 10.1016/j.compbiomed.2021.105119. Epub 2021 Dec 7.
10
A secondary approach with conventional medicines and supplements to recuperate current COVID-19 status.用常规药物和补充剂来恢复当前 COVID-19 状况的次要方法。
Biomed Pharmacother. 2021 Oct;142:111956. doi: 10.1016/j.biopha.2021.111956. Epub 2021 Jul 27.